NEW YORK, June 14 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM - News) today announced results for its fiscal year ended March 31, 2006. For the year ended March 31, 2006, revenues were $3,575,000, as compared to $5,931,000 for the year ended March 31, 2005. The decrease was primarily attributable to revenues from research and testing agreements. Loss from operations for the year ended March 31, 2006 was $15,736,000, as compared to a loss from operations of $13,569,000 for the year ended March 31, 2005. The loss was largely due to expenses related to the Phase III clinical trials. Net loss attributable to common stockholders for the year ended March 31, 2006 was $16,290,000, or $1.37 per share, compared to a loss of $14,013,000, or $1.32 per share, in the previous year.
